- Conditions
- Severe Renal Impairment
- Interventions
- RANEXA
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Miami, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 457–480
of 9,283
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Volunteers
- Interventions
- ASP1617, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Nipah Virus Infection
- Interventions
- mRNA -1215
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Advanced Solid Tumors, Breast Cancer, Breast Carcinoma, Breast Neoplasms, ER Positive Breast Cancer, Cervical Cancers, Cervical Neoplasms, Cervical Carcinoma, Triple Negative Breast Cancer, Gynecologic Cancers, Gynecologic Neoplasm, Endometrial Cancer, Endometrial Neoplasm, Endometrial Carcinoma (EC), Fallopian Cancer, Ovarian Carcinoma, Ovarian Cancer, Ovarian Neoplasms, Prostate Cancers, Prostate Carcinoma, Solid Tumors, Neoplasms, Neoplasms by Site, Breast Diseases, Uterine Neoplasms, Genital Neoplasms, Female, Urogenital Neoplasms
- Interventions
- ATV-1601, ATV-1601 + Fulvestrant
- Drug · Combination Product
- Lead sponsor
- Atavistik Bio, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Lake Mary, Florida • Boston, Massachusetts + 2 more
- Conditions
- Pneumonia, Pneumococcal
- Interventions
- V116, Pneumovax™23
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Coral Gables, Florida + 15 more
- Conditions
- Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)
- Interventions
- Nezulcitinib (TD-0903) Dose A, Nezulcitinib (TD-0903) Dose B
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE, Prevention of Pneumococcal-induced Acute Otitis Media
- Interventions
- Inactivated whole-cell Streptococcus pneumoniae vaccine, Placebo
- Biological · Drug
- Lead sponsor
- Serum Life Science Europe GmbH
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma
- Interventions
- Zilovertamab vedotin
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 6 Months to 25 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 14 more
- Conditions
- Lysosomal Storage Diseases, Cystinosis
- Interventions
- CTNS-RD-04 (including CTNS-RD-04-LB manufactured with LentiBOOST)
- Genetic
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia
- Interventions
- AB8939, Venetoclax
- Drug
- Lead sponsor
- AB Science
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL)
- Interventions
- TRU-016 (anti-CD37 protein therapeutic)
- Drug
- Lead sponsor
- Aptevo Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Augusta, Georgia • Boston, Massachusetts + 4 more
- Conditions
- Peripheral Arterial Occlusive Disease
- Interventions
- Not listed
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Severe Hepatic Impairment
- Interventions
- Vortioxetine
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- Interleukin-15 Superagonist (N-803), CIML NK cell Infusion, Ipilimumab, Cetuximab
- Drug · Biological
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Non-small Cell Lung Cancer, EGFR-mutant Lung Cancers
- Interventions
- osimertinib, Bevacizumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Solid Tumors
- Interventions
- ABT-263, erlotinib, irinotecan (3-week schedule), irinotecan (weekly schedule)
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 4
- States / cities
- Santa Monica, California • Detroit, Michigan • San Antonio, Texas + 1 more
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC, PDAC, CRC, Relapsed Cancer, Refractory Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Stage III Colorectal Cancer, Stage IV Colorectal Cancer, Stage III NSCLC, Stage IV NSCLC, KRAS Mutation-Related Tumors
- Interventions
- BMF-219
- Drug
- Lead sponsor
- Biomea Fusion Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 19
- States / cities
- Goodyear, Arizona • Encinitas, California • La Jolla, California + 15 more
- Conditions
- Healthy Volunteers
- Interventions
- Treatment A - 400 mg Fasting, Treatment B - 400 mg Fed, Treatment C - 200 mg Fed
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Advanced Solid Tumor
- Interventions
- UCT-03-008
- Drug
- Lead sponsor
- 1200 Pharma, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Torrance, California • Atlanta, Georgia + 2 more
- Conditions
- Acne Vulgaris
- Interventions
- Tazarotene Foam, Vehicle Foam
- Drug
- Lead sponsor
- Stiefel, a GSK Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 254 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (UC), Bladder Cancer, Mesothelioma, Pleural Mesothelioma, Peritoneal Mesothelioma, Non-Small Cell Lung Cancer NSCLC, Pancreatic Cancer, Biliary Tract Carcinoma
- Interventions
- IDE892, IDE397
- Drug
- Lead sponsor
- IDEAYA Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 23
- States / cities
- Goodyear, Arizona • Phoenix, Arizona • Duarte, California + 19 more
- Conditions
- Bacterial Infections
- Interventions
- Cefiderocol/Xeruborbactam
- Drug
- Lead sponsor
- Qpex Biopharma, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Migraine
- Interventions
- CVT-427 (zolmitriptan inhalation powder)
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 3
- States / cities
- North Dartmouth, Massachusetts • Lincoln, Nebraska • Dallas, Texas
- Conditions
- Blasts 10-19 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, High Risk Chronic Myelomonocytic Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent High Risk Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia, Refractory High Risk Myelodysplastic Syndrome
- Interventions
- Liposome-encapsulated Daunorubicin-Cytarabine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas